x | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
Delaware | 22-0790350 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
PART I—FINANCIAL INFORMATION | |
Item 1. | |
Item 2. | |
Item 3. | |
Item 4. | |
PART II—OTHER INFORMATION | |
Item 1. | |
Item 1A. | |
Item 2. | |
Item 6. | |
Three Months Ended March 31, | |||||||
EARNINGS | 2017 | 2016 | |||||
Net product sales | $ | 4,580 | $ | 3,964 | |||
Alliance and other revenues | 349 | 427 | |||||
Total Revenues | 4,929 | 4,391 | |||||
Cost of products sold | 1,259 | 1,052 | |||||
Marketing, selling and administrative | 1,074 | 1,068 | |||||
Research and development | 1,288 | 1,136 | |||||
Other (income)/expense | (647 | ) | (520 | ) | |||
Total Expenses | 2,974 | 2,736 | |||||
Earnings Before Income Taxes | 1,955 | 1,655 | |||||
Provision for Income Taxes | 429 | 449 | |||||
Net Earnings | 1,526 | 1,206 | |||||
Net Earnings/(Loss) Attributable to Noncontrolling Interest | (48 | ) | 11 | ||||
Net Earnings Attributable to BMS | $ | 1,574 | $ | 1,195 | |||
Earnings per Common Share | |||||||
Basic | $ | 0.95 | $ | 0.72 | |||
Diluted | $ | 0.94 | $ | 0.71 | |||
Cash dividends declared per common share | $ | 0.39 | $ | 0.38 |
Three Months Ended March 31, | |||||||
COMPREHENSIVE INCOME | 2017 | 2016 | |||||
Net Earnings | $ | 1,526 | $ | 1,206 | |||
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings: | |||||||
Derivatives qualifying as cash flow hedges | (29 | ) | (86 | ) | |||
Pension and postretirement benefits | 83 | (161 | ) | ||||
Available-for-sale securities | 6 | 13 | |||||
Foreign currency translation | 29 | 9 | |||||
Other Comprehensive Income/(Loss) | 89 | (225 | ) | ||||
Comprehensive Income | 1,615 | 981 | |||||
Comprehensive Income/(Loss) Attributable to Noncontrolling Interest | (48 | ) | 11 | ||||
Comprehensive Income Attributable to BMS | $ | 1,663 | $ | 970 |
ASSETS | March 31, 2017 | December 31, 2016 | |||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 3,910 | $ | 4,237 | |||
Marketable securities | 2,199 | 2,113 | |||||
Receivables | 5,494 | 5,543 | |||||
Inventories | 1,384 | 1,241 | |||||
Prepaid expenses and other | 628 | 570 | |||||
Total Current Assets | 13,615 | 13,704 | |||||
Property, plant and equipment | 5,020 | 4,980 | |||||
Goodwill | 6,875 | 6,875 | |||||
Other intangible assets | 1,276 | 1,385 | |||||
Deferred income taxes | 2,618 | 2,996 | |||||
Marketable securities | 2,685 | 2,719 | |||||
Other assets | 848 | 1,048 | |||||
Total Assets | $ | 32,937 | $ | 33,707 | |||
LIABILITIES | |||||||
Current Liabilities: | |||||||
Short-term debt obligations | $ | 1,197 | $ | 992 | |||
Accounts payable | 1,503 | 1,664 | |||||
Accrued liabilities | 4,777 | 5,271 | |||||
Deferred income | 837 | 762 | |||||
Income taxes payable | 180 | 152 | |||||
Total Current Liabilities | 8,494 | 8,841 | |||||
Deferred income | 528 | 547 | |||||
Income taxes payable | 948 | 973 | |||||
Pension and other liabilities | 1,195 | 1,283 | |||||
Long-term debt | 7,237 | 5,716 | |||||
Total Liabilities | 18,402 | 17,360 | |||||
Commitments and contingencies (Note 17) | |||||||
EQUITY | |||||||
Bristol-Myers Squibb Company Shareholders’ Equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 221 | 221 | |||||
Capital in excess of par value of stock | 1,337 | 1,725 | |||||
Accumulated other comprehensive loss | (2,414 | ) | (2,503 | ) | |||
Retained earnings | 33,658 | 33,513 | |||||
Less cost of treasury stock | (18,386 | ) | (16,779 | ) | |||
Total Bristol-Myers Squibb Company Shareholders’ Equity | 14,416 | 16,177 | |||||
Noncontrolling interest | 119 | 170 | |||||
Total Equity | 14,535 | 16,347 | |||||
Total Liabilities and Equity | $ | 32,937 | $ | 33,707 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Cash Flows From Operating Activities: | |||||||
Net earnings | $ | 1,526 | $ | 1,206 | |||
Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities: | |||||||
Depreciation and amortization, net | 193 | 65 | |||||
Deferred income taxes | (70 | ) | (246 | ) | |||
Stock-based compensation | 45 | 47 | |||||
Impairment charges | 78 | 19 | |||||
Pension settlements and amortization | 52 | 39 | |||||
Divestiture gains and royalties | (276 | ) | (507 | ) | |||
Asset acquisition charges | — | 100 | |||||
Other adjustments | 33 | (10 | ) | ||||
Changes in operating assets and liabilities: | |||||||
Receivables | (246 | ) | (424 | ) | |||
Inventories | (71 | ) | (44 | ) | |||
Accounts payable | (114 | ) | (77 | ) | |||
Deferred income | 74 | 235 | |||||
Income taxes payable | 414 | 52 | |||||
Other | (777 | ) | (683 | ) | |||
Net Cash Provided by/(Used in) Operating Activities | 861 | (228 | ) | ||||
Cash Flows From Investing Activities: | |||||||
Sale and maturities of marketable securities | 1,163 | 1,760 | |||||
Purchase of marketable securities | (1,204 | ) | (523 | ) | |||
Capital expenditures | (291 | ) | (242 | ) | |||
Divestiture and other proceeds | 241 | 439 | |||||
Acquisition and other payments | (112 | ) | (8 | ) | |||
Net Cash Provided by/(Used in) Investing Activities | (203 | ) | 1,426 | ||||
Cash Flows From Financing Activities: | |||||||
Short-term borrowings, net | 192 | (33 | ) | ||||
Issuance of long-term debt | 1,488 | — | |||||
Repurchase of common stock | (2,000 | ) | (231 | ) | |||
Dividends | (655 | ) | (641 | ) | |||
Other | (38 | ) | (45 | ) | |||
Net Cash Used in Financing Activities | (1,013 | ) | (950 | ) | |||
Effect of Exchange Rates on Cash and Cash Equivalents | 28 | 11 | |||||
Increase/(Decrease) in Cash and Cash Equivalents | (327 | ) | 259 | ||||
Cash and Cash Equivalents at Beginning of Period | 4,237 | 2,385 | |||||
Cash and Cash Equivalents at End of Period | $ | 3,910 | $ | 2,644 |
Accounting Standard Update | Effective Date |
Revenue from Contracts with Customers | January 1, 2018 |
Recognition and Measurement of Financial Assets and Liabilities | January 1, 2018 |
Definition of a Business | January 1, 2018 |
Leases | January 1, 2019 |
Financial Instruments - Measurement of Credit Losses | January 1, 2020 |
Goodwill Impairment Testing | January 1, 2020 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Prioritized Brands | |||||||
Opdivo | $ | 1,127 | $ | 704 | |||
Eliquis | 1,101 | 734 | |||||
Orencia | 535 | 475 | |||||
Sprycel | 463 | 407 | |||||
Yervoy | 330 | 263 | |||||
Empliciti | 53 | 28 | |||||
Established Brands | |||||||
Hepatitis C Franchise | 162 | 427 | |||||
Baraclude | 282 | 291 | |||||
Sustiva Franchise | 184 | 273 | |||||
Reyataz Franchise | 193 | 221 | |||||
Other Brands | 499 | 568 | |||||
Total Revenues | $ | 4,929 | $ | 4,391 | |||
Net product sales | $ | 4,580 | $ | 3,964 | |||
Alliance revenues | 297 | 409 | |||||
Other revenues | 52 | 18 | |||||
Total Revenues | $ | 4,929 | $ | 4,391 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Revenues from alliances: | |||||||
Net product sales | $ | 1,576 | $ | 1,231 | |||
Alliance revenues | 297 | 409 | |||||
Total Revenues | $ | 1,873 | $ | 1,640 | |||
Payments to/(from) alliance partners: | |||||||
Cost of products sold | $ | 624 | $ | 476 | |||
Marketing, selling and administrative | (9 | ) | 1 | ||||
Research and development | — | 33 | |||||
Other (income)/expense | (246 | ) | (253 | ) | |||
Noncontrolling interest, pretax | 2 | 2 |
Selected Alliance Balance Sheet information: | |||||||
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Receivables - from alliance partners | $ | 897 | $ | 903 | |||
Accounts payable - to alliance partners | 600 | 555 | |||||
Deferred income from alliances(a) | 1,251 | 1,194 |
(a) | Includes unamortized upfront, milestone and other licensing proceeds, revenue deferrals attributed to Atripla* and undelivered elements of diabetes business divestiture proceeds. Amortization of deferred income (primarily related to alliances) was $20 million and $82 million for the three months ended March 31, 2017 and 2016, respectively. |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Interest expense | $ | 45 | $ | 43 | |||
Investment income | (33 | ) | (24 | ) | |||
Provision for restructuring | 164 | 4 | |||||
Litigation and other settlements(a) | (484 | ) | 43 | ||||
Equity in net income of affiliates | (18 | ) | (26 | ) | |||
Divestiture gains | (127 | ) | (270 | ) | |||
Royalties and licensing income | (199 | ) | (254 | ) | |||
Transition and other service fees | (7 | ) | (53 | ) | |||
Pension charges | 33 | 22 | |||||
Intangible asset impairments | — | 15 | |||||
Other | (21 | ) | (20 | ) | |||
Other (income)/expense | $ | (647 | ) | $ | (520 | ) |
(a) | Includes BMS's share of a patent-infringement litigation settlement of $481 million related to Merck's PD-1 antibody Keytruda*. |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Employee termination costs | $ | 161 | $ | 4 | |||
Other termination costs | 3 | — | |||||
Provision for restructuring | 164 | 4 | |||||
Accelerated depreciation | 70 | 14 | |||||
Asset impairments | 2 | — | |||||
Other shutdown costs | — | 3 | |||||
Total charges | $ | 236 | $ | 21 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Cost of products sold | $ | — | $ | 4 | |||
Research and development | 72 | 13 | |||||
Other (income)/expense | 164 | 4 | |||||
Total charges | $ | 236 | $ | 21 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Liability at January 1 | $ | 114 | $ | 125 | |||
Charges | 170 | 8 | |||||
Change in estimates | (6 | ) | (4 | ) | |||
Provision for restructuring | 164 | 4 | |||||
Foreign currency translation | 1 | — | |||||
Spending | (44 | ) | (33 | ) | |||
Liability at March 31 | $ | 235 | $ | 96 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Earnings Before Income Taxes | $ | 1,955 | $ | 1,655 | |||
Provision for Income Taxes | 429 | 449 | |||||
Effective tax rate | 21.9 | % | 27.1 | % |
Three Months Ended March 31, | |||||||
Amounts in Millions, Except Per Share Data | 2017 | 2016 | |||||
Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation | $ | 1,574 | $ | 1,195 | |||
Weighted-average common shares outstanding – basic | 1,662 | 1,669 | |||||
Incremental shares attributable to share-based compensation plans | 9 | 11 | |||||
Weighted-average common shares outstanding – diluted | 1,671 | 1,680 | |||||
Earnings per Common Share: | |||||||
Basic | $ | 0.95 | $ | 0.72 | |||
Diluted | $ | 0.94 | $ | 0.71 |
March 31, 2017 | December 31, 2016 | ||||||||||||||
Dollars in Millions | Level 1 | Level 2 | Level 1 | Level 2 | |||||||||||
Cash and cash equivalents - Money market and other securities | $ | — | $ | 3,256 | $ | — | $ | 3,532 | |||||||
Marketable securities: | |||||||||||||||
Certificates of deposit | — | 419 | — | 27 | |||||||||||
Commercial paper | — | 480 | — | 750 | |||||||||||
Corporate debt securities | — | 3,869 | — | 3,947 | |||||||||||
Equity funds | — | 109 | — | 101 | |||||||||||
Fixed income funds | — | 7 | — | 7 | |||||||||||
Derivative assets | — | 29 | — | 75 | |||||||||||
Equity investments | 30 | — | 24 | — | |||||||||||
Derivative liabilities | — | (24 | ) | — | (30 | ) |
March 31, 2017 | December 31, 2016 | ||||||||||||||||||||||||||||||
Dollars in Millions | Amortized Cost | Gross Unrealized | Amortized Cost | Gross Unrealized | |||||||||||||||||||||||||||
Gains | Losses | Fair Value | Gains | Losses | Fair Value | ||||||||||||||||||||||||||
Certificates of deposit | $ | 419 | $ | — | $ | — | $ | 419 | $ | 27 | $ | — | $ | — | $ | 27 | |||||||||||||||
Commercial paper | 480 | — | — | 480 | 750 | — | — | 750 | |||||||||||||||||||||||
Corporate debt securities | 3,864 | 11 | (6 | ) | 3,869 | 3,945 | 10 | (8 | ) | 3,947 | |||||||||||||||||||||
Equity investments | 31 | 4 | (5 | ) | 30 | 31 | — | (7 | ) | 24 | |||||||||||||||||||||
Total | $ | 4,794 | $ | 15 | $ | (11 | ) | $ | 4,798 | $ | 4,753 | $ | 10 | $ | (15 | ) | $ | 4,748 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Current marketable securities(a) | $ | 2,199 | $ | 2,113 | |||
Non-current marketable securities(b) | 2,685 | 2,719 | |||||
Other assets | 30 | 24 | |||||
Total | $ | 4,914 | $ | 4,856 |
(a) | The fair value option for financial assets was elected for investments in equity and fixed income funds. The fair value of these investments were $116 million at March 31, 2017 and $108 million at December 31, 2016 and included in current marketable securities. |
(b) | All non-current marketable securities mature within five years as of March 31, 2017 and December 31, 2016. |
March 31, 2017 | December 31, 2016 | ||||||||||||||||||||||||||||||
Asset(a) | Liability(b) | Asset(a) | Liability(b) | ||||||||||||||||||||||||||||
Dollars in Millions | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | |||||||||||||||||||||||
Derivatives designated as hedging instruments: | |||||||||||||||||||||||||||||||
Interest rate swap contracts | $ | — | $ | — | $ | 1,505 | $ | (5 | ) | $ | 750 | $ | 1 | $ | 755 | $ | (3 | ) | |||||||||||||
Forward starting interest rate swap contracts | — | — | — | — | 500 | 8 | 250 | (11 | ) | ||||||||||||||||||||||
Foreign currency forward contracts | 507 | 29 | 536 | (17 | ) | 967 | 66 | 198 | (9 | ) | |||||||||||||||||||||
Derivatives not designated as hedging instruments: | |||||||||||||||||||||||||||||||
Foreign currency forward contracts | 71 | — | 137 | (2 | ) | 106 | — | 360 | (7 | ) |
(a) | Included in prepaid expenses and other and other assets. |
(b) | Included in accrued liabilities and pension and other liabilities. |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Bank drafts and short-term borrowings | $ | 448 | $ | 243 | |||
Current portion of long-term debt | 749 | 749 | |||||
Total | $ | 1,197 | $ | 992 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Principal Value | $ | 7,800 | $ | 6,261 | |||
Adjustments to Principal Value: | |||||||
Fair value of interest rate swap contracts | (5 | ) | (2 | ) | |||
Unamortized basis adjustment from swap terminations | 280 | 287 | |||||
Unamortized bond discounts and issuance costs | (89 | ) | (81 | ) | |||
Total | $ | 7,986 | $ | 6,465 | |||
Current portion of long-term debt | $ | 749 | $ | 749 | |||
Long-term debt | 7,237 | 5,716 |
Amounts in Millions | 2017 | ||
Principal Value: | |||
1.600% Notes due 2019 | $ | 750 | |
3.250% Notes due 2027 | 750 | ||
Total | $ | 1,500 | |
Proceeds net of discount and deferred loan issuance costs | $ | 1,488 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Trade receivables | $ | 4,247 | $ | 3,948 | |||
Less charge-backs and cash discounts | (123 | ) | (126 | ) | |||
Less bad debt allowances | (41 | ) | (48 | ) | |||
Net trade receivables | 4,083 | 3,774 | |||||
Alliance receivables | 897 | 903 | |||||
Prepaid and refundable income taxes | 243 | 627 | |||||
Other | 271 | 239 | |||||
Receivables | $ | 5,494 | $ | 5,543 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Finished goods | $ | 415 | $ | 310 | |||
Work in process | 1,038 | 988 | |||||
Raw and packaging materials | 230 | 264 | |||||
Total inventories | $ | 1,683 | $ | 1,562 | |||
Inventories | $ | 1,384 | $ | 1,241 | |||
Other assets | 299 | 321 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Land | $ | 107 | $ | 107 | |||
Buildings | 4,952 | 4,930 | |||||
Machinery, equipment and fixtures | 3,324 | 3,287 | |||||
Construction in progress | 938 | 849 | |||||
Gross property, plant and equipment | 9,321 | 9,173 | |||||
Less accumulated depreciation | (4,301 | ) | (4,193 | ) | |||
Property, plant and equipment | $ | 5,020 | $ | 4,980 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Licenses | $ | 564 | $ | 564 | |||
Developed technology rights | 2,357 | 2,357 | |||||
Capitalized software | 1,344 | 1,441 | |||||
IPRD | 32 | 107 | |||||
Gross other intangible assets | 4,297 | 4,469 | |||||
Less accumulated amortization | (3,021 | ) | (3,084 | ) | |||
Other intangible assets | $ | 1,276 | $ | 1,385 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | ||||||
Rebates and returns | $ | 1,677 | $ | 1,680 | ||||
Dividends | 646 | 660 | ||||||
Research and development | 620 | 718 | ||||||
Employee compensation and benefits | 361 | 818 | ||||||
Branded Prescription Drug Fee | 257 | 234 | ||||||
Restructuring | 182 | 90 | ||||||
Royalties | 181 | 246 | ||||||
Pension and postretirement benefits | 41 | 44 | ||||||
Litigation and other settlements | 36 | 43 | ||||||
Other | 776 | 738 | ||||||
Accrued liabilities | $ | 4,777 | $ | 5,271 |
Common Stock | Capital in Excess of Par Value of Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock | Noncontrolling Interest | ||||||||||||||||||||||||
Dollars and Shares in Millions | Shares | Par Value | Shares | Cost | |||||||||||||||||||||||||
Balance at January 1, 2016 | 2,208 | $ | 221 | $ | 1,459 | $ | (2,468 | ) | $ | 31,613 | 539 | $ | (16,559 | ) | $ | 158 | |||||||||||||
Net earnings | — | — | — | — | 1,195 | — | — | 11 | |||||||||||||||||||||
Other comprehensive loss | — | — | — | (225 | ) | — | — | — | — | ||||||||||||||||||||
Cash dividends | — | — | — | — | (632 | ) | — | — | — | ||||||||||||||||||||
Stock repurchase program | — | — | — | — | — | 4 | (231 | ) | — | ||||||||||||||||||||
Stock compensation | — | — | 44 | — | — | (4 | ) | (31 | ) | — | |||||||||||||||||||
Distributions | — | — | — | — | — | — | — | (4 | ) | ||||||||||||||||||||
Balance at March 31, 2016 | 2,208 | $ | 221 | $ | 1,503 | $ | (2,693 | ) | $ | 32,176 | 539 | $ | (16,821 | ) | $ | 165 | |||||||||||||
Balance at December 31, 2016 | 2,208 | $ | 221 | $ | 1,725 | $ | (2,503 | ) | $ | 33,513 | 536 | $ | (16,779 | ) | $ | 170 | |||||||||||||
Accounting change - cumulative effect(a) | — | — | — | — | (787 | ) | — | — | — | ||||||||||||||||||||
Adjusted balance at January 1, 2017 | 2,208 | $ | 221 | $ | 1,725 | $ | (2,503 | ) | $ | 32,726 | 536 | $ | (16,779 | ) | $ | 170 | |||||||||||||
Net earnings | — | — | — | — | 1,574 | — | — | 11 | |||||||||||||||||||||
Other comprehensive income | — | — | — | 89 | — | — | — | — | |||||||||||||||||||||
Cash dividends | — | — | — | — | (642 | ) | — | — | — | ||||||||||||||||||||
Stock repurchase program | — | — | (400 | ) | — | — | 29 | (1,600 | ) | — | |||||||||||||||||||
Stock compensation | — | — | 12 | — | — | (4 | ) | (7 | ) | — | |||||||||||||||||||
Variable interest entity | — | — | — | — | — | — | — | (59 | ) | ||||||||||||||||||||
Distributions | — | — | — | — | — | — | — | (3 | ) | ||||||||||||||||||||
Balance at March 31, 2017 | 2,208 | $ | 221 | $ | 1,337 | $ | (2,414 | ) | $ | 33,658 | 561 | $ | (18,386 | ) | $ | 119 |
(a) | Refer to "—Note 1. Basis of Presentation and Recently Issued Accounting Standards" for additional information. |
2017 | 2016 | ||||||||||||||||||||||
Pretax | Tax | After tax | Pretax | Tax | After tax | ||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||
Derivatives qualifying as cash flow hedges: | |||||||||||||||||||||||
Unrealized losses | $ | (18 | ) | $ | 7 | $ | (11 | ) | $ | (126 | ) | $ | 42 | $ | (84 | ) | |||||||
Reclassified to net earnings(a) | (22 | ) | 4 | (18 | ) | (4 | ) | 2 | (2 | ) | |||||||||||||
Derivatives qualifying as cash flow hedges | (40 | ) | 11 | (29 | ) | (130 | ) | 44 | (86 | ) | |||||||||||||
Pension and postretirement benefits: | |||||||||||||||||||||||
Actuarial gains/(losses) | 58 | (18 | ) | 40 | (292 | ) | 103 | (189 | ) | ||||||||||||||
Amortization(b) | 19 | 3 | 22 | 17 | (3 | ) | 14 | ||||||||||||||||
Curtailments and settlements(c) | 33 | (12 | ) | 21 | 22 | (8 | ) | 14 | |||||||||||||||
Pension and postretirement benefits | 110 | (27 | ) | 83 | (253 | ) | 92 | (161 | ) | ||||||||||||||
Available-for-sale securities | 9 | (3 | ) | 6 | 27 | (14 | ) | 13 | |||||||||||||||
Foreign currency translation | 21 | 8 | 29 | 2 | 7 | 9 | |||||||||||||||||
$ | 100 | $ | (11 | ) | $ | 89 | $ | (354 | ) | $ | 129 | $ | (225 | ) |
(a) | Included in cost of products sold |
(b) | Included in cost of products sold, research and development and marketing, selling and administrative expenses |
(c) | Included in other (income)/expense |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Derivatives qualifying as cash flow hedges | $ | 9 | $ | 38 | |||
Pension and other postretirement benefits | (2,014 | ) | (2,097 | ) | |||
Available-for-sale securities | (1 | ) | (7 | ) | |||
Foreign currency translation | (408 | ) | (437 | ) | |||
Accumulated other comprehensive loss | $ | (2,414 | ) | $ | (2,503 | ) |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Service cost – benefits earned during the year | $ | 6 | $ | 6 | |||
Interest cost on projected benefit obligation | 48 | 51 | |||||
Expected return on plan assets | (103 | ) | (104 | ) | |||
Amortization of prior service credits | (1 | ) | (1 | ) | |||
Amortization of net actuarial loss | 21 | 19 | |||||
Curtailments and settlements | 33 | 22 | |||||
Special termination benefits | — | 1 | |||||
Net periodic benefit cost/(credit) | $ | 4 | $ | (6 | ) |
Three Months Ended March 31, | |||||||
Dollars in Millions, except per share data | 2017 | 2016 | |||||
Total Revenues | $ | 4,929 | $ | 4,391 | |||
Diluted Earnings Per Share | |||||||
GAAP | 0.94 | 0.71 | |||||
Non-GAAP | 0.84 | 0.74 |
Product | Date | Approval |
Opdivo | March 2017 | Approval for the treatment of recurrent or metastatic HNC in Japan, received by our alliance partner, Ono. |
February 2017 | FDA approval for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. |
Three Months Ended March 31, | |||||||||||||
Total Revenues | 2017 vs. 2016 | ||||||||||||
Dollars in Millions | 2017 | 2016 | Total Change | Foreign Exchange(b) | |||||||||
United States | $ | 2,738 | $ | 2,537 | 8 | % | — | ||||||
Europe | 1,146 | 870 | 32 | % | (5 | )% | |||||||
Rest of the World | 925 | 840 | 10 | % | 1 | % | |||||||
Other(a) | 120 | 144 | (17 | )% | N/A | ||||||||
Total | $ | 4,929 | $ | 4,391 | 12 | % | (1 | )% |
(a) | Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations. |
(b) | Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales. |
Three Months Ended March 31, | ||||||||||
Dollars in Millions | 2017 | 2016 | % Change | |||||||
Gross product sales | $ | 5,862 | $ | 4,966 | 18 | % | ||||
GTN adjustments: | ||||||||||
Charge-backs and cash discounts | (438 | ) | (352 | ) | 24 | % | ||||
Medicaid and Medicare rebates | (384 | ) | (260 | ) | 48 | % | ||||
Other rebates, returns, discounts and adjustments | (460 | ) | (390 | ) | 18 | % | ||||
Total GTN adjustments | (1,282 | ) | (1,002 | ) | 28 | % | ||||
Net product sales | $ | 4,580 | $ | 3,964 | 16 | % | ||||
GTN adjustments percentage | 22 | % | 20 | % | 2 | % | ||||
U.S. | 28 | % | 25 | % | 3 | % | ||||
Non-U.S. | 12 | % | 12 | % | — |
Three Months Ended March 31, | ||||||||||
Dollars in Millions | 2017 | 2016 | % Change | |||||||
Prioritized Brands | ||||||||||
Opdivo | $ | 1,127 | $ | 704 | 60 | % | ||||
U.S. | 761 | 594 | 28 | % | ||||||
Non-U.S. | 366 | 110 | ** | |||||||
Eliquis | 1,101 | 734 | 50 | % | ||||||
U.S. | 699 | 468 | 49 | % | ||||||
Non-U.S. | 402 | 266 | 51 | % | ||||||
Orencia | 535 | 475 | 13 | % | ||||||
U.S. | 362 | 321 | 13 | % | ||||||
Non-U.S. | 173 | 154 | 12 | % | ||||||
Sprycel | 463 | 407 | 14 | % | ||||||
U.S. | 247 | 210 | 18 | % | ||||||
Non-U.S. | 216 | 197 | 10 | % | ||||||
Yervoy | 330 | 263 | 25 | % | ||||||
U.S. | 243 | 199 | 22 | % | ||||||
Non-U.S. | 87 | 64 | 36 | % | ||||||
Empliciti | 53 | 28 | 89 | % | ||||||
U.S. | 36 | 28 | 29 | % | ||||||
Non-U.S. | 17 | — | N/A | |||||||
Established Brands | ||||||||||
Hepatitis C Franchise | 162 | 427 | (62 | )% | ||||||
U.S. | 42 | 259 | (84 | )% | ||||||
Non-U.S. | 120 | 168 | (29 | )% | ||||||
Baraclude | 282 | 291 | (3 | )% | ||||||
U.S. | 14 | 17 | (18 | )% | ||||||
Non-U.S. | 268 | 274 | (2 | )% | ||||||
Sustiva Franchise | 184 | 273 | (33 | )% | ||||||
U.S. | 153 | 228 | (33 | )% | ||||||
Non-U.S. | 31 | 45 | (31 | )% | ||||||
Reyataz Franchise | 193 | 221 | (13 | )% | ||||||
U.S. | 88 | 120 | (27 | )% | ||||||
Non-U.S. | 105 | 101 | 4 | % | ||||||
Other Brands | 499 | 568 | (12 | )% | ||||||
U.S. | 93 | 93 | — | |||||||
Non-U.S. | 406 | 475 | (15 | )% |
• | U.S. revenues increased due to higher demand. We expect increased competition for Opdivo in 2017. |
• | International revenues increased due to higher demand as a result of launches of additional indications and approvals in new countries. |
• | U.S. and international revenues increased due to higher demand resulting from increased commercial acceptance of novel oral anticoagulants and market share gains. |
• | U.S. revenues increased due to higher average net selling prices and demand. |
• | International revenues increased due to higher demand. |
• | U.S. revenues increased due to higher demand and average net selling prices. |
• | International revenues increased due to higher demand. |
• | U.S. revenues increased due to higher demand and average net selling prices. |
• | International revenues increased due to higher demand. |
• | Empliciti was launched in the U.S. in December 2015, in the EU in May 2016 and in Japan in September 2016. |
• | U.S. and international revenues decreased due to lower demand resulting from increased competition. |
• | International revenues remained relatively flat. |
• | U.S. revenues continued to decrease due to lower demand resulting from increased competition. The loss of exclusivity for Sustiva is expected in December 2017 which may result in the termination of the joint venture agreement with Gilead and may further reduce revenues beyond 2017. |
• | International revenues continued to decrease due to Sustiva's loss of exclusivity in Europe. |
• | U.S. revenues continued to decrease due to lower demand resulting from increased competition. The loss of exclusivity is expected in December 2017 and we may experience a higher decline in revenues in future periods due to generic competition. |
• | International revenues increased due to the timing of government purchases in certain countries partially offset by lower demand resulting from increased competition. |
• | International revenues decreased due to out-licensing and divestiture of certain other brands. |
Three Months Ended March 31, | ||||||||||
Dollars in Millions | 2017 | 2016 | % Change | |||||||
Cost of products sold | $ | 1,259 | $ | 1,052 | 20 | % | ||||
Marketing, selling and administrative | 1,074 | 1,068 | 1 | % | ||||||
Research and development | 1,288 | 1,136 | 13 | % | ||||||
Other (income)/expense | (647 | ) | (520 | ) | 24 | % | ||||
Total Expenses | $ | 2,974 | $ | 2,736 | 9 | % |
• | IPRD impairment charges were $75 million in 2017 for FS102 which was part of our alliance with F-Star Alpha. |
• | Accelerated depreciation was $70 million in 2017 and $13 million in 2016 as a result of the expected exit of additional R&D sites in the U.S. Accelerated depreciation results from the reduction in the estimated useful lives of the related assets for each site at various dates through 2020 and is expected to approximate $270 million in 2017. |
• | License and asset acquisition charges were $50 million in 2017 and $125 million in 2016 including a $100 million milestone payment to former shareowners of Flexus in 2016. |
• | Litigation and other settlements were income of $484 million in 2017 and expense of $43 million in 2016 including BMS's share of a patent-infringement litigation settlement related to Merck's PD-1 antibody Keytruda* in 2017. |
• | Restructuring charges were $164 million in 2017 and $4 million in 2016. In October 2016, the Company announced changes to its operating model to drive the Company’s continued success in the near- and long-term through a more focused investment in commercial opportunities for key brands and markets, a competitive and more agile R&D organization that can accelerate the pipeline, streamlined operations and realigned manufacturing capabilities that broaden biologics capabilities to reflect the current and future portfolio as well as streamline and simplify our small-molecule supply network. The new operating model will enable the Company to deliver the strategic, financial and operational flexibility necessary to invest in the highest priorities across the Company. Restructuring charges of approximately $300 million are expected to be incurred in 2017 for all actions in addition to accelerated depreciation impacts resulting from early site exits. |
• | Divestiture gains were $127 million in 2017 and $270 million in 2016 including additional contingent consideration for the diabetes business ($100 million) in 2017 and the investigational HIV medicines business ($269 million) in 2016. |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Earnings Before Income Taxes | $ | 1,955 | $ | 1,655 | |||
Provision for Income Taxes | 429 | 449 | |||||
Effective tax rate | 21.9 | % | 27.1 | % |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Cost of products sold(a) | $ | — | $ | 4 | |||
License and asset acquisition charges | 50 | 125 | |||||
IPRD impairments | 75 | — | |||||
Accelerated depreciation and other | 72 | 13 | |||||
Research and development | 197 | 138 | |||||
Provision for restructuring | 164 | 4 | |||||
Litigation and other settlements | (481 | ) | 43 | ||||
Divestiture gains | (100 | ) | (269 | ) | |||
Pension charges | 33 | 22 | |||||
Intangible asset impairments | — | 15 | |||||
Other (income)/expense | (384 | ) | (185 | ) | |||
Decrease to pretax income | (187 | ) | (43 | ) | |||
Income taxes on specified items | 72 | 83 | |||||
Increase/(decrease) to net earnings | (115 | ) | 40 | ||||
Noncontrolling interest | (59 | ) | — | ||||
Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation | $ | (174 | ) | $ | 40 |
(a) | Specified items in cost of products sold are accelerated depreciation, asset impairment and other shutdown costs. |
Three Months Ended March 31, | |||||||
Dollars in Millions, except per share data | 2017 | 2016 | |||||
Net Earnings Attributable to BMS used for Diluted EPS Calculation – GAAP | $ | 1,574 | $ | 1,195 | |||
Specified Items | (174 | ) | 40 | ||||
Net Earnings used for Diluted EPS Calculation – Non-GAAP | $ | 1,400 | $ | 1,235 | |||
Average Common Shares Outstanding – Diluted | 1,671 | 1,680 | |||||
Diluted Earnings Per Share – GAAP | $ | 0.94 | $ | 0.71 | |||
Diluted EPS Attributable to Specified Items | (0.10 | ) | 0.03 | ||||
Diluted Earnings Per Share – Non-GAAP | $ | 0.84 | $ | 0.74 |
Dollars in Millions | March 31, 2017 | December 31, 2016 | |||||
Cash and cash equivalents | $ | 3,910 | $ | 4,237 | |||
Marketable securities – current | 2,199 | 2,113 | |||||
Marketable securities – non-current | 2,685 | 2,719 | |||||
Cash, cash equivalents and marketable securities | 8,794 | 9,069 | |||||
Short-term debt obligations | (1,197 | ) | (992 | ) | |||
Long-term debt | (7,237 | ) | (5,716 | ) | |||
Net cash position | $ | 360 | $ | 2,361 |
Three Months Ended March 31, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Cash flow provided by/(used in): | |||||||
Operating activities | $ | 861 | $ | (228 | ) | ||
Investing activities | (203 | ) | 1,426 | ||||
Financing activities | (1,013 | ) | (950 | ) |
• | Lower income tax payments of approximately $500 million; and |
• | BMS's share of litigation settlement proceeds of $481 million related to Merck's PD-1 antibody Keytruda*. |
• | Lower net proceeds from sales, purchases and maturities of marketable securities of $1.3 billion. |
• | Higher repurchase of common stock of $1.8 billion. |
• | Long-term debt proceeds of $1.5 billion in 2017; and |
• | Higher net short-term borrowings of approximately $200 million in 2017, consisting primarily of a short-term revolving line of credit. |
Product | Indication | Date | Developments |
Opdivo | Biliary Tract Cancer | April 2017 | BMS and Ono announced Opdivo was designated for the treatment of biliary tract cancer under the Sakigake Designation System in Japan, which offers priority consultation and review. |
cHL | April 2017 | FDA approval for an updated indication for Opdivo for the treatment of adult patients with cHL that have relapsed or progressed after auto-HSCT and brentuximab vedotin, or three or more lines of systemic therapy that includes auto-HSCT. | |
CRC | April 2017 | Announced FDA accepted for priority review a supplemental Biologics License Application that seeks to extend the use of Opdivo in previously treated mismatch repair deficient or microsatellite instability high metastatic CRC. The FDA action date is August 2, 2017. | |
Gastric Cancer | January 2017 | Announced results of ONO-4538-12, a Phase III trial evaluating Opdivo in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy. Ono, our alliance partner, conducted the trial. | |
GBM | April 2017 | Announced CheckMate-143, a randomized Phase III trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of GBM did not meet its primary endpoint of improved overall survival over bevacizumab monotherapy. | |
HNC | April 2017 | BMS and Incyte announced the companies will advance their clinical development program evaluating the combination of epacadostat, Incyte's investigational oral selective IDO1 enzyme inhibitor, with Opdivo into a Phase III registrational study in first-line HNC. | |
March 2017 | Approval for the treatment of recurrent or metastatic HNC in Japan, received by our alliance partner, Ono. | ||
March 2017 | Announced the CHMP has recommended the approval of Opdivo as monotherapy for the treatment of SCCHN in adults progressing on or after platinum-based therapy. | ||
mUC | April 2017 | Announced the CHMP has recommended the approval of Opdivo as monotherapy for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. | |
February 2017 | FDA approval for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. | ||
NSCLC | April 2017 | Announced five-year overall survival data from study CA209-003, a Phase I study evaluating Opdivo in patients with previously treated advanced NSCLC. | |
April 2017 | BMS and Incyte announced the companies will advance their clinical development program evaluating the combination of epacadostat with Opdivo into a Phase III registrational study in first-line NSCLC across the spectrum of PD-L1 expression. | ||
RCC | February 2017 | BMS and Exelixis announced a clinical development collaboration to evaluate Cabometyx* (cabozantinib), Exelixis's small molecule inhibitor of receptor tyrosine kinases, with Opdivo, either alone or in combination with Yervoy. The agreement is expected to include a Phase III trial in first-line RCC with additional trials planned in bladder cancer, HCC and potentially other tumor types. | |
Opdivo+Yervoy | Melanoma | April 2017 | Announced overall survival data from CheckMate-067, a Phase III trial evaluating Opdivo alone or in combination with Yervoy in patients with previously untreated advanced melanoma. |
Eliquis | Non-Valvular Atrial Fibrillation | March 2017 | Announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. |
Period | Total Number of Shares Purchased(a) | Average Price Paid per Share(a) | Total Number of Shares Purchased as Part of Publicly Announced Programs(b) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs(b) | |||||||||
Dollars in Millions, Except Per Share Data | |||||||||||||
January 1 to 31, 2017 | 27,223 | $ | 58.45 | — | $ | 4,137 | |||||||
February 1 to 28, 2017 | 28,700,454 | $ | 55.77 | 28,689,260 | $ | 2,137 | |||||||
March 1 to 31, 2017 | 1,338,495 | $ | 58.27 | — | $ | 2,137 | |||||||
Three months ended March 31, 2017 | 30,066,172 | 28,689,260 |
(a) | Includes shares repurchased as part of publicly announced programs and shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program. |
(b) | In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of common stock and in June 2012 increased its authorization for the repurchase of common stock by an additional $3.0 billion. In October 2016, the Board of Directors approved a new share repurchase program authorizing the repurchase of an additional $3.0 billion of common stock. The stock repurchase program does not have an expiration date. Refer to “Item 1. Financial Statements—Note 15. Equity" for information on the accelerated share repurchase agreements. |
Exhibit No. | Description | |
101. | The following financial statements from the Bristol-Myers Squibb Company Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) consolidated statements of earnings, (ii) consolidated statements of comprehensive income, (iii) consolidated balance sheets, (iv) consolidated statements of cash flows, and (v) the notes to the consolidated financial statements. |
2016 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2016 |
AstraZeneca | AstraZeneca PLC |
auto-HSCT | autologous hematopoietic stem cell transplantation |
Biogen | Biogen Inc. |
Cardioxyl | Cardioxyl Pharmaceuticals, Inc. |
cHL | classical Hodgkin lymphoma |
CHMP | Committee for Medicinal Products for Human Use |
CRC | colorectal cancer |
CytomX | CytomX Therapeutics, Inc. |
EPO | European Patent Office |
EPS | earnings per share |
EU | European Union |
Exelixis | Exelixis, Inc. |
FASB | Financial Accounting Standards Board |
FDA | U.S. Food and Drug Administration |
Flexus | Flexus Biosciences, Inc. |
F-Star Alpha | F-Star Alpha Ltd. |
GAAP | U.S. generally accepted accounting principles |
GBM | glioblastoma multiforme |
Gilead | Gilead Sciences, Inc. |
GTN | Gross-to-Net |
HCC | Hepatocellular carcinoma |
HIV | human immunodeficiency virus |
HNC | head and neck cancer |
iPierian | iPerian, Inc. |
Incyte | Incyte Corporation |
IO | immuno-oncology |
IPRD | In-process research and development |
Merck | Merck & Co., Inc. |
mUC | metastatic urothelial carcinoma |
NKT | natural killer T cells |
NSCLC | non-small cell lung cancer |
PD-1 | programmed death receptor-1 |
OCI | Other Comprehensive Income |
Ono | Ono Pharmaceutical Co., Ltd. |
Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017 |
R&D | Research and Development |
RA | rheumatoid arthritis |
RCC | renal cell carcinoma |
Reckitt | Reckitt Benckiser Group plc |
SCCHN | squamous cell carcinoma of the head and neck |
SEC | Securities and Exchange Commission |
UK | United Kingdom |
U.S. | United States |
BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT) | ||||
Date: | April 27, 2017 | By: | /s/ Giovanni Caforio | |
Giovanni Caforio Chief Executive Officer | ||||
Date: | April 27, 2017 | By: | /s/ Charles Bancroft | |
Charles Bancroft Chief Financial Officer |
Ratio of Earnings to Fixed Charges: | Three Months Ended March 31, 2017 | Year Ended December 31, | |||||||||||||||||
2016 | 2015 | 2014 | 2013 | ||||||||||||||||
Dollars in Millions | |||||||||||||||||||
Earnings | |||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 1,955 | $ | 5,915 | $ | 2,077 | $ | 2,381 | $ | 2,891 | |||||||||
Less: | |||||||||||||||||||
Noncontrolling interest in pre-tax income/(loss) of | |||||||||||||||||||
subsidiaries that have not incurred fixed charges | (73 | ) | 16 | 51 | 38 | 36 | |||||||||||||
Equity in net income of affiliates | 18 | 77 | 83 | 107 | 166 | ||||||||||||||
Capitalized interest | 3 | 10 | 2 | 3 | — | ||||||||||||||
Adjusted Income | 2,007 | 5,812 | 1,941 | 2,233 | 2,689 | ||||||||||||||
Add: | |||||||||||||||||||
Fixed charges | 58 | 226 | 231 | 254 | 255 | ||||||||||||||
Distributed income of equity investments | 23 | 99 | 105 | 153 | 149 | ||||||||||||||
Total Earnings | $ | 2,088 | $ | 6,137 | $ | 2,277 | $ | 2,640 | $ | 3,093 | |||||||||
Fixed Charges | |||||||||||||||||||
Interest expense | $ | 45 | $ | 167 | $ | 184 | $ | 203 | $ | 199 | |||||||||
Capitalized interest | 3 | 10 | 2 | 3 | — | ||||||||||||||
One-third of rental expense(1) | 10 | 49 | 45 | 48 | 56 | ||||||||||||||
Total Fixed Charges | $ | 58 | $ | 226 | $ | 231 | $ | 254 | $ | 255 | |||||||||
Ratio of Earnings to Fixed Charges | 36.00 | 27.15 | 9.86 | 10.39 | 12.13 |
1. | I have reviewed Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017; |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
/s/ Giovanni Caforio |
Giovanni Caforio Chief Executive Officer |
1. | I have reviewed Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017; |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
/s/ Charles Bancroft |
Charles Bancroft Chief Financial Officer |
/s/ Giovanni Caforio |
Giovanni Caforio Chief Executive Officer |
/s/ Charles Bancroft |
Charles Bancroft Chief Financial Officer |
Document and Entity Information |
3 Months Ended |
---|---|
Mar. 31, 2017
shares
| |
Document and Entity Information [Abstract] | |
Entity Registrant Name | BRISTOL MYERS SQUIBB CO |
Entity Central Index Key | 0000014272 |
Entity Well-known Seasoned Issuer | Yes |
Entity Current Reporting Status | Yes |
Entity Voluntary Filers | No |
Entity Filer Category | Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 1,647,434,458 |
Document Type | 10-Q |
Document Period End Date | Mar. 31, 2017 |
Document Fiscal Year Focus | 2017 |
Document Fiscal Period Focus | Q1 |
Current Fiscal Year End Date | --12-31 |
Amendment Flag | false |
CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Income Statement [Abstract] | ||
Net product sales | $ 4,580 | $ 3,964 |
Alliance and other revenues | 349 | 427 |
Total revenues | 4,929 | 4,391 |
Cost of products sold | 1,259 | 1,052 |
Marketing, selling and administrative | 1,074 | 1,068 |
Research and development | 1,288 | 1,136 |
Other (income)/expense | (647) | (520) |
Total Expenses | 2,974 | 2,736 |
Earnings Before Income Taxes | 1,955 | 1,655 |
Provision for Income Taxes | 429 | 449 |
Net Earnings | 1,526 | 1,206 |
Net Earnings/(Loss) Attributable to Noncontrolling Interest | (48) | 11 |
Net Earnings Attributable to BMS | $ 1,574 | $ 1,195 |
Earnings per Common Share | ||
Basic | $ 0.95 | $ 0.72 |
Diluted | 0.94 | 0.71 |
Cash dividends declared per common share | $ 0.39 | $ 0.38 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
COMPREHENSIVE INCOME | ||
Net Earnings | $ 1,526 | $ 1,206 |
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings [Abstract] | ||
Derivatives qualifying as cash flow hedges | (29) | (86) |
Pension and postretirement benefits | 83 | (161) |
Available-for-sale securities | 6 | 13 |
Foreign currency translation | 29 | 9 |
Other Comprehensive Income/(Loss) | 89 | (225) |
Comprehensive Income | 1,615 | 981 |
Comprehensive Income/(Loss) Attributable to Noncontrolling Interest | (48) | 11 |
Comprehensive Income Attributable to BMS | $ 1,663 | $ 970 |
BASIS OF PRESENTATION |
3 Months Ended | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||
Basis Of Presentation [Text Block] | BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2017 and December 31, 2016 and the results of operations and cash flows for the three months ended March 31, 2017 and 2016. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining sales rebate and return accruals; legal contingencies; income taxes; determining if an acquisition or divestiture is a business or an asset; and pension and postretirement benefits. Actual results may differ from estimates. Certain prior period amounts were reclassified to conform to the current period presentation. The consolidated statements of cash flows previously presented interest rate swap contract terminations and issuance of common stock as separate line items within cash flows from financing activities which are now presented as components of other financing activities. The reclassifications provide a more concise financial statement presentation and additional information is disclosed in the notes if material. Recently Adopted Accounting Standards Share-based Payment Transactions Amended guidance for share-based payment transactions was adopted in the first quarter of 2017. Net excess tax benefits of approximately $20 million were recognized prospectively as a reduction of tax expense rather than capital in excess of par value of stock. Net excess tax benefits are also presented as an operating cash flow rather than a financing cash flow and cash payments to tax authorities in connection with shares withheld for statutory tax withholding requirements are presented as a financing cash flow rather than an operating cash flow. The changes in cash flow presentation were applied retrospectively and increased operating cash flows and decreased financing cash flows by $99 million in the first quarter of 2017 and $158 million in the first quarter of 2016. Income Tax Accounting for Intra-entity Transfers of Assets Other Than Inventory Amended guidance on income tax accounting for intra-entity transfers of assets other than inventory was early adopted in the first quarter of 2017 on a modified retrospective approach. The amended guidance requires tax consequences of these transfers be recognized in the period the transfer takes place. Net reductions to prepaid and deferred tax assets pertaining to pre-2017 internal transfers of intellectual property of $787 million were adjusted through retained earnings as a cumulative effect of an accounting change which will reduce the annual tax expense by $86 million beginning in 2017. In addition, the tax consequences of additional internal transfers of intellectual property that may occur in the future will be included in income tax expense upon transfer and not amortized in subsequent periods. Recently Issued Accounting Standards Presentation of Net Periodic Pension and Postretirement Benefits In March 2017, the FASB issued amended guidance requiring all net periodic benefit components for defined benefit pension and other postretirement plans other than service costs to be recorded outside of income from operations (other income). The guidance is effective in 2018 on a retrospective basis with early adoption permitted. The Company expects that annual cost of products sold; marketing selling and administrative; and research and development expenses will increase by approximately $150 million in the aggregate with a corresponding offset in other income. In addition, the following recently issued accounting standards have not been adopted. Refer to the 2016 Form 10-K for additional information and their potential impacts.
|
BUSINESS SEGMENT INFORMATION |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segment Information [Text Block] | BUSINESS SEGMENT INFORMATION BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods. Product revenues and the composition of total revenues were as follows:
|
ALLIANCES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alliances [Text Block] | ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. We refer to these collaborations as alliances and our partners as alliance partners. Products sold through alliance arrangements in certain markets include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, Empliciti, Sustiva (Atripla*) and certain other brands. Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
Specific information pertaining to each of our significant alliances is discussed in our 2016 Form 10-K, including their nature and purpose, the significant rights and obligations of the parties and specific accounting policy elections. Significant developments and updates related to alliances during the three months ended March 31, 2017 are set forth below. AstraZeneca BMS received $100 million from AstraZeneca as additional contingent consideration for the diabetes business divestiture upon achievement of a regulatory approval milestone in the first quarter of 2017 (included in other income). F-Star Alpha In the first quarter of 2017, BMS discontinued development of FS102 (an anti-HER2 antibody fragment) which was in Phase I development for the treatment of breast and gastric cancer. BMS will not exercise its option to purchase F-Star Alpha which was previously consolidated by BMS as a variable interest entity. As a result, an IPRD charge of $75 million was included in R&D expense and attributed to noncontrolling interest. |
LICENSING ARRANGEMENTS |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Acquisitions, Divestitures and Licensing Arrangements [Abstract] | |
Licensing Arrangements [Text Block] | LICENSING ARRANGEMENTS CytomX In April 2017, BMS added up to eight additional targets to its strategic collaboration with CytomX to discover novel therapies using CytomX’s proprietary Probody platform. As part of the original May 2014 collaboration to discover, develop and commercialize Probody therapeutics, BMS selected four oncology targets, including CTLA-4. Pursuant to the expanded agreement, CytomX will grant BMS exclusive worldwide rights to develop and commercialize Probody therapeutics for up to eight additional targets. BMS paid CytomX $75 million for the rights to the initial four targets which was expensed as R&D prior to 2017. BMS will pay $200 million to CytomX for access to the eight additional targets in May 2017 which will be included in R&D expense in the second quarter of 2017. BMS will also reimburse CytomX for certain research costs over the collaboration period, pay up to $448 million upon achievement of contingent development, regulatory and sales milestone events for each collaboration target and future royalties if a product is approved and commercialized. Biogen In April 2017, BMS agreed to out-license to Biogen exclusive rights to develop and commercialize BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy. Upon closing, Biogen will pay $300 million to BMS which will be included in other income. BMS will also be entitled to contingent development, regulatory and sales based milestone payments of up to $410 million if achieved as well as future royalties if the product is ultimately approved and commercialized. BMS originally acquired the rights to this compound in 2014 through its acquisition of iPierian. Biogen will assume all of BMS’s remaining obligations to the former stockholders of iPierian. The transaction is expected to close in the second quarter of 2017 upon obtaining customary regulatory approvals. Roche In April 2017, BMS agreed to out-license to Roche exclusive rights to develop and commercialize BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy. Upon closing, Roche will pay $170 million to BMS which will be included in other income. BMS will also be entitled to contingent development and regulatory milestone payments of up to $205 million if achieved and future royalties if the product is ultimately approved and commercialized. The transaction is expected to close in the second quarter of 2017 upon obtaining customary regulatory approvals. |
OTHER (INCOME)/EXPENSE |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (Income)/Expense [Text Block] | OTHER (INCOME)/EXPENSE
|
RESTRUCTURING |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Charges [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING In October 2016, the Company announced a restructuring plan to evolve and streamline its operating model and expects to incur charges in connection with employee workforce reductions and early site exits. The charges are expected to be incurred through 2020, range between $1.5 billion to $2.0 billion and consist of employee termination benefit costs, contract termination costs, plant and equipment accelerated depreciation and impairment charges and other site shutdown costs. Cash outlays in connection with these actions are expected to be approximately 40% to 50% of the total charges. Charges of approximately $310 million have been recognized for these actions since the announcement (approximately $220 million for the three months ended March 31, 2017), primarily resulting from employee workforce reductions and accelerated depreciation from expected early site exits. Restructuring charges are recognized upon meeting certain criteria, including finalization of committed plans, reliable estimates and discussions with local works councils in certain markets. Other restructuring charges recognized prior to the above actions were primarily related to specialty care transformation initiatives designed to create a more simplified organization across all functions and geographic markets. In addition, accelerated depreciation and other charges were incurred in connection with early exits of a manufacturing site in Ireland and R&D site in the U.S. Employee workforce reductions were approximately 900 and 100 for the three months ended March 31, 2017 and 2016, respectively, across all geographic regions for manufacturing, selling, administrative and R&D personnel. The following tables summarize the charges and activity related to the restructuring actions:
|
INCOME TAXES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Text Block] | INCOME TAXES
The effective tax rate is lower than the U.S. statutory rate of 35% primarily attributable to undistributed earnings of certain foreign subsidiaries in low tax jurisdictions that have been considered or are expected to be indefinitely reinvested offshore. These undistributed earnings primarily relate to operations in Switzerland, Ireland and Puerto Rico. If these undistributed earnings are repatriated to the U.S. in the future, or if it were determined that such earnings are to be remitted in the foreseeable future, additional tax provisions would be required. Due to complexities in the tax laws and assumptions that would have to be made, it is not practicable to estimate the amounts of income taxes that would have to be provided. Reforms to U.S. tax laws related to foreign earnings have been proposed and if adopted, may increase taxes, which could reduce the results of operations and cash flows. BMS operates under a favorable tax grant in Puerto Rico not scheduled to expire prior to 2023. Jurisdictional tax rates and other tax impacts attributed to R&D charges, divestiture transactions and other discrete pretax items increased the effective tax rate by 1.7% and 4.4% in the three months ended March 31, 2017 and 2016, respectively, including non-deductible R&D asset acquisition charges and goodwill allocated to business divestitures. The tax impact for discrete items are reflected immediately and are not considered in estimating the annual effective tax rate. The adoption of the amended guidance for intra-entity transfers of assets other than inventory and share-based payment transactions reduced the effective tax rate by 2.1% in the three months ended March 31, 2017. Refer to "—Note 1. Basis of Presentation and Recently Issued Accounting Standards" for additional information. BMS is currently under examination by a number of tax authorities which have proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. It is reasonably possible that the total amount of unrecognized tax benefits at March 31, 2017 could decrease in the range of approximately $255 million to $315 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. It is also reasonably possible that new issues will be raised by tax authorities which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time. |
EARNINGS PER SHARE |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Text Block] | EARNINGS PER SHARE
|
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Text Block] | FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
As further described in "Note 9. Financial Instruments and Fair Value Measurements" in our 2016 Form 10-K, our fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs), (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs) or (3) unobservable inputs (Level 3 inputs). There were no Level 3 financial assets or liabilities as of March 31, 2017 and December 31, 2016. Available-for-sale Securities The following table summarizes available-for-sale securities:
Qualifying Hedges and Non-Qualifying Derivatives The following table summarizes the fair value of outstanding derivatives:
Cash Flow Hedges — The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro ($584 million) and Japanese yen ($252 million) at March 31, 2017. BMS terminated forward starting interest rate swap contracts in the first quarter of 2017 with an aggregate notional value of $750 million. The proceeds and related gain were not material. Net Investment Hedges — Non-U.S. dollar borrowings of €950 million ($1,026 million) are designated to hedge euro currency exposures of the net investment in certain foreign affiliates. Fair Value Hedges — The notional amount of fixed-to-floating interest rate swap contracts terminated was $500 million in 2016 generating proceeds of $43 million (including accrued interest). Debt Obligations Short-term debt obligations includes:
Long-term debt and the current portion of long-term debt includes:
The fair value of debt was $8,411 million at March 31, 2017 and $6,932 million at December 31, 2016 valued using Level 2 inputs. Interest payments were $43 million and $33 million for the three months ended March 31, 2017 and 2016, respectively, net of amounts related to interest rate swap contracts. On February 27, 2017, BMS issued senior unsecured notes in a registered public offering. The notes rank equally in right of payment with all of BMS's existing and future senior unsecured indebtedness. BMS may redeem the notes, in whole or in part, at any time prior to maturity at a predetermined redemption price. The following table summarizes the note issuances:
|
RECEIVABLES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Text Block] | RECEIVABLES
Non-U.S. receivables sold on a nonrecourse basis were $120 million and $159 million for the three months ended March 31, 2017 and 2016, respectively. Receivables from our three largest pharmaceutical wholesalers in the U.S. represented 65% and 66% of total trade receivables at March 31, 2017 and December 31, 2016, respectively. |
INVENTORIES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Text Block] | INVENTORIES
Other assets include inventory pending regulatory approval of $58 million at March 31, 2017 and $54 million at December 31, 2016 and other amounts expected to remain on-hand beyond one year. |
PROPERTY, PLANT AND EQUIPMENT |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Text Block] | PROPERTY, PLANT AND EQUIPMENT
Depreciation expense was $166 million and $103 million for the three months ended March 31, 2017 and 2016, respectively. |
OTHER INTANGIBLE ASSETS |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Text Block] | OTHER INTANGIBLE ASSETS
Amortization expense was $47 million and $44 million for the three months ended March 31, 2017 and 2016, respectively. |
ACCRUED LIABILITIES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | ACCRUED LIABILITIES
|
EQUITY |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | EQUITY
BMS has a stock repurchase program authorized by its Board of Directors allowing for repurchases in the open market or through private transactions, including plans established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. The stock repurchase program does not have an expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method. In February 2017, BMS executed accelerated share repurchase agreements to repurchase an aggregate $2 billion of common stock as part of our existing share repurchase authorization. The agreements were funded through a combination of debt and cash. Approximately 29 million shares of BMS common stock, representing approximately 80% of the notional amount of the agreements, were delivered to BMS and included in treasury stock. The agreements are expected to settle during the second quarter of 2017, upon which additional shares of common stock may be delivered to BMS or, under certain circumstances, BMS may be required to make a cash payment or may elect to deliver shares of BMS common stock to the counterparties. The total number of shares to be delivered or the amount of such payment, as well as the final average price per share, will be based on the volume-weighted average price, less a discount, of BMS common stock during the term of the transaction. The components of other comprehensive income/(loss) were as follows:
The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
|
PENSION AND POSTRETIREMENT BENEFIT PLANS |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Other Postretirement Benefits [Text Block] | PENSION AND POSTRETIREMENT BENEFIT PLANS The net periodic benefit cost/(credit) of defined benefit pension plans includes:
Pension settlement charges were recognized after determining that the annual lump sum payments will likely exceed the annual interest and service costs for the primary and certain other U.S. pension plans. The charges included the acceleration of a portion of unrecognized actuarial losses. Non-current pension liabilities were $490 million at March 31, 2017 and $600 million at December 31, 2016. Defined contribution plan expense in the U.S. was $44 million and $42 million for the three months ended March 31, 2017 and 2016, respectively. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings and Contingencies [Text Block] | LEGAL PROCEEDINGS AND CONTINGENCIES The Company and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. The Company recognizes accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. These matters involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage. Legal proceedings that are material or that the Company believes could become material are described below. Although the Company believes it has substantial defenses in these matters, there can be no assurance that there will not be an increase in the scope of pending matters or that any future lawsuits, claims, government investigations or other legal proceedings will not be material. Unless otherwise noted, the Company is unable to assess the outcome of the respective litigation nor is it able to provide an estimated range of potential loss. Furthermore, failure to enforce our patent rights would likely result in substantial decreases in the respective product revenues from generic competition. INTELLECTUAL PROPERTY Plavix* — Australia As previously disclosed, Sanofi was notified that, in August 2007, GenRx Proprietary Limited (GenRx) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc. (Apotex), has since changed its name to Apotex. In August 2007, Apotex filed an application in the Federal Court of Australia (the Federal Court) seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court granted Sanofi’s injunction. A subsidiary of the Company was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the Apotex case, and a trial occurred in April 2008. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. The Company and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (Full Court) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims which have stayed the Federal Court’s ruling. Apotex filed a notice of appeal appealing the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. A hearing on the appeals occurred in February 2009. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In November 2009, the Company and Sanofi applied to the High Court of Australia (High Court) for special leave to appeal the judgment of the Full Court. In March 2010, the High Court denied the Company and Sanofi’s request to hear the appeal of the Full Court decision. The case has been remanded to the Federal Court for further proceedings related to damages sought by Apotex. The Australian government has intervened in this matter and is also seeking damages for alleged losses experienced during the period when the injunction was in place. The Company and Apotex have settled the Apotex case, and the case has been dismissed. The Australian government's claim is still pending and a trial has been scheduled for August 2017. It is not possible at this time to predict the outcome of the Australian government’s claim or its impact on the Company. Sprycel - European Union In May 2013, Apotex, Actavis Group PTC ehf, Generics [UK] Limited (Mylan) and an unnamed company filed oppositions in the EPO seeking revocation of European Patent No. 1169038 (the ‘038 patent) covering dasatinib, the active ingredient in Sprycel. The ‘038 patent is scheduled to expire in April 2020 (excluding potential term extensions). On January 20, 2016, the Opposition Division of the EPO revoked the ‘038 patent. In May 2016, the Company appealed the EPO’s decision to the EPO Board of Appeal. In February 2017, the EPO Board of Appeal upheld the Opposition Division's decision, and revoked the ‘038 patent. Orphan drug exclusivity and data exclusivity for Sprycel in the EU expired in November 2016. The EPO Board of Appeal's decision does not affect the validity of our other Sprycel patents within and outside Europe, including different patents that cover the monohydrate form of dasatinib and the use of dasatinib to treat chronic myelogenous leukemia (CML). Additionally, in February 2017, the EPO Board of Appeal reversed and remanded an invalidity decision on European Patent No. 1610780 and its claim to the use of dasatinib to treat CML, which the EPO's Opposition Division had revoked in October 2012. The Company intends to take appropriate legal actions to protect Sprycel. We may experience a decline in European revenues in the event that generic dasatinib product enters the market. Anti-PD-1 Antibody Patent Oppositions and Litigation On January 20, 2017, BMS and Ono announced the companies have signed a global patent license agreement with Merck to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda* (pembrolizumab). The agreement resulted in the dismissal with prejudice of all patent litigation between the companies pertaining to Keytruda*. BMS and Ono had asserted in litigation that Merck’s sale of Keytruda* infringed the companies’ patents relating to the use of PD-1 antibodies to treat cancer in the U.S., Europe (UK, Netherlands, France, Germany, Ireland, Spain and Switzerland), Australia and Japan. As part of the agreement, Merck made an initial payment of $625 million to BMS and Ono, of which BMS received $481 million. Merck is also obligated to pay ongoing royalties on global sales of Keytruda* of 6.5% from January 1, 2017 through December 31, 2023, and 2.5% from January 1, 2024 through December 31, 2026. Under the agreement, the companies have also granted certain rights to each other under their respective patent portfolios pertaining to PD-1. Payments and royalties are shared between BMS and Ono on a 75/25 percent allocation, respectively after adjusting for each parties' legal fees. In September 2015, Dana-Farber Cancer Institute (Dana-Farber) filed a complaint in Massachusetts federal court seeking to correct the inventorship of five related U.S. patents directed to methods of treating cancer using a PD-1 antibody. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. Eliquis Patent Litigation In February, March and April 2017, twenty-five generic companies sent the Company Paragraph-IV certification letters informing the Company that they had filed abbreviated new drug applications (ANDAs) seeking approval of generic versions of Eliquis. As a result, the three Eliquis patents listed in the FDA Orange Book have now been challenged, including a composition of matter patent claiming apixaban specifically and a formulation patent. In April 2017, the Company, along with its partner Pfizer, initiated patent lawsuits under the Hatch-Waxman Act against all generic filers in federal district courts in Delaware and West Virginia. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits The Company and certain affiliates of Sanofi are defendants in consumer protection and/or false advertising actions brought by several states relating to the sales and promotion of Plavix*. It is not possible at this time to reasonably assess the outcome of these lawsuits or their potential impact on the Company. PRODUCT LIABILITY LITIGATION The Company is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, the Company also faces unfiled claims involving its products. Plavix* As previously disclosed, the Company and certain affiliates of Sanofi are defendants in a number of individual lawsuits in various state and federal courts claiming personal injury damage allegedly sustained after using Plavix*. Currently, over 5,300 claims involving injury plaintiffs as well as claims by spouses and/or other beneficiaries, are filed in state and federal courts in various states including California, New Jersey, Delaware and New York. In February 2013, the Judicial Panel on Multidistrict Litigation granted the Company and Sanofi’s motion to establish a multi-district litigation (MDL) to coordinate Federal pretrial proceedings in Plavix* product liability and related cases in New Jersey Federal Court. It is not possible at this time to reasonably assess the outcome of these lawsuits or the potential impact on the Company. Byetta* Amylin, a former subsidiary of the Company, and Lilly are co-defendants in product liability litigation related to Byetta*. To date, there are over 500 separate lawsuits pending on behalf of approximately 2,000 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The Company has agreed in principle to resolve over 15 of these claims. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta*, primarily pancreatic cancer and pancreatitis, and, in some cases, claiming alleged wrongful death. The majority of cases were pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (JCCP). In November 2015, the defendants' motion for summary judgment based on federal preemption was granted in both the MDL and the JCCP. The plaintiffs in the MDL have appealed to the U.S. Court of Appeals for the Ninth Circuit and the JCCP plaintiffs have appealed to the California Court of Appeal. Amylin has product liability insurance covering a substantial number of claims involving Byetta* and any additional liability to Amylin with respect to Byetta* is expected to be shared between the Company and AstraZeneca. It is not possible to reasonably predict the outcome of any lawsuit, claim or proceeding or the potential impact on the Company. Abilify* The Company and Otsuka are co-defendants in product liability litigation related to Abilify. Plaintiffs allege Abilify caused them to engage in compulsive gambling and other impulse control disorders. There have been over 160 cases filed in state and federal courts and several additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation has consolidated the federal court cases for pretrial purposes in the United States District Court for the Northern District of Florida. Eliquis The Company and Pfizer are co-defendants in product liability litigation related to Eliquis. Plaintiffs assert claims, including claims for wrongful death, as a result of bleeding they allege was caused by their use of Eliquis. There have been over 130 cases filed in state and federal courts in the United States and two cases filed in Canada. The Judicial Panel on Multidistrict Litigation has consolidated the federal court cases for pretrial purposes in the United States District Court for the Southern District of New York. SHAREHOLDER DERIVATIVE LITIGATION Since December 2015, three shareholder derivative lawsuits were filed in New York state court against certain officers and directors of the Company. The plaintiffs allege, among other things, breaches of fiduciary duty surrounding the Company’s previously disclosed October 2015 civil settlement with the Securities and Exchange Commission of alleged Foreign Corrupt Practices Act violations in China in which the Company agreed to a payment of approximately $14.7 million in disgorgement, penalties and interest. Two of the lawsuits have been dismissed, and the Company has filed a motion to dismiss the remaining lawsuit. GOVERNMENT INVESTIGATIONS Like other pharmaceutical companies, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which BMS operates. As a result, the Company, from time to time, is subject to various governmental inquiries and investigations. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government investigations. The most significant investigations conducted by government agencies, of which the Company is aware, are listed below. Abilify* State Attorneys General Investigation In March 2009, the Company received a letter from the Delaware Attorney General’s Office advising of a multi-state coalition (Coalition) investigating whether certain Abilify* marketing practices violated those respective states’ consumer protection statutes. The Company and the Executive Committee of the Coalition have reached a settlement in this matter, and all but one of the states (New Mexico) that are members of the Coalition are participating in the settlement. Consent decrees were entered into with all participating states in December 2016 and settlement payments have been issued to all participating states. ENVIRONMENTAL PROCEEDINGS As previously reported, the Company is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at the Company’s current or former sites or at waste disposal or reprocessing facilities operated by third parties. CERCLA Matters With respect to CERCLA matters for which the Company is responsible under various state, federal and foreign laws, the Company typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and the Company accrues liabilities when they are probable and reasonably estimable. The Company estimated its share of future costs for these sites to be $63 million at December 31, 2016, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The $63 million includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site. |
BASIS OF PRESENTATION (Policies) |
3 Months Ended | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||
Nature of Business | Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2017 and December 31, 2016 and the results of operations and cash flows for the three months ended March 31, 2017 and 2016. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. |
||||||||||||||||||
Use of Estimates | Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining sales rebate and return accruals; legal contingencies; income taxes; determining if an acquisition or divestiture is a business or an asset; and pension and postretirement benefits. Actual results may differ from estimates. |
||||||||||||||||||
Reclassifications | Certain prior period amounts were reclassified to conform to the current period presentation. The consolidated statements of cash flows previously presented interest rate swap contract terminations and issuance of common stock as separate line items within cash flows from financing activities which are now presented as components of other financing activities. The reclassifications provide a more concise financial statement presentation and additional information is disclosed in the notes if material. |
||||||||||||||||||
New Accounting Pronouncements | Recently Adopted Accounting Standards Share-based Payment Transactions Amended guidance for share-based payment transactions was adopted in the first quarter of 2017. Net excess tax benefits of approximately $20 million were recognized prospectively as a reduction of tax expense rather than capital in excess of par value of stock. Net excess tax benefits are also presented as an operating cash flow rather than a financing cash flow and cash payments to tax authorities in connection with shares withheld for statutory tax withholding requirements are presented as a financing cash flow rather than an operating cash flow. The changes in cash flow presentation were applied retrospectively and increased operating cash flows and decreased financing cash flows by $99 million in the first quarter of 2017 and $158 million in the first quarter of 2016. Income Tax Accounting for Intra-entity Transfers of Assets Other Than Inventory Amended guidance on income tax accounting for intra-entity transfers of assets other than inventory was early adopted in the first quarter of 2017 on a modified retrospective approach. The amended guidance requires tax consequences of these transfers be recognized in the period the transfer takes place. Net reductions to prepaid and deferred tax assets pertaining to pre-2017 internal transfers of intellectual property of $787 million were adjusted through retained earnings as a cumulative effect of an accounting change which will reduce the annual tax expense by $86 million beginning in 2017. In addition, the tax consequences of additional internal transfers of intellectual property that may occur in the future will be included in income tax expense upon transfer and not amortized in subsequent periods. Recently Issued Accounting Standards Presentation of Net Periodic Pension and Postretirement Benefits In March 2017, the FASB issued amended guidance requiring all net periodic benefit components for defined benefit pension and other postretirement plans other than service costs to be recorded outside of income from operations (other income). The guidance is effective in 2018 on a retrospective basis with early adoption permitted. The Company expects that annual cost of products sold; marketing selling and administrative; and research and development expenses will increase by approximately $150 million in the aggregate with a corresponding offset in other income. In addition, the following recently issued accounting standards have not been adopted. Refer to the 2016 Form 10-K for additional information and their potential impacts.
|
BUSINESS SEGMENT INFORMATION (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Product Revenues [Table Text Block] | Product revenues and the composition of total revenues were as follows:
|
ALLIANCES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Alliance Arrangements [Table Text Block] | Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
|
OTHER (INCOME)/EXPENSE (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Other Income Expense [Table Text Block] |
|
RESTRUCTURING (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Costs [Table Text Block] | The following tables summarize the charges and activity related to the restructuring actions:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve by Type of Cost [Table Text Block] |
|
INCOME TAXES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Provision for Income Taxes [Table Text Block] |
|
EARNINGS PER SHARE (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-sale Securities [Table Text Block] | The following table summarizes available-for-sale securities:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derivatives and Fair Value [Table Text Block] | The following table summarizes the fair value of outstanding derivatives:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Short-term Debt [Table Text Block] | Short-term debt obligations includes:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value and Other Adjustments to Long Term Debt [Table Text Block] | Long-term debt and the current portion of long-term debt includes:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Note Issuances [Table Text Block] | The following table summarizes the note issuances:
|
RECEIVABLES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Receivables [Table Text Block] |
|
INVENTORIES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Table Text Block] |
|
PROPERTY, PLANT AND EQUIPMENT (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Table Text Block] |
|
OTHER INTANGIBLE ASSETS (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Intangible Assets By Major Class [Table Text Block] |
|
ACCRUED LIABILITIES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Liabilities [Table Text Block] |
|
EQUITY (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock by Class [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Comprehensive Income Loss [Table Text Block] | The components of other comprehensive income/(loss) were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income Loss [Table Text Block] | The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
|
PENSION AND POSTRETIREMENT BENEFIT PLANS (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Defined Benefit Plans Disclosures [Table Text Block] | The net periodic benefit cost/(credit) of defined benefit pension plans includes:
|
LICENSING ARRANGEMENTS (Details) - Licensing Agreements [Member] |
3 Months Ended |
---|---|
Mar. 31, 2017
USD ($)
| |
CytomX [Member] | |
Licensing Arrangements [Line Items] | |
Number of additional targets added | $ 8 |
Number of original targets | 4 |
R&D payments prior to 2017 | 75,000,000 |
License arrangement upfront payment | 200,000,000 |
Potential contingent milestones | 448,000,000 |
Biogen [Member] | |
Licensing Arrangements [Line Items] | |
Proceeds from out-licensed arrangements | 300,000,000 |
Potential milestone receipts | 410,000,000 |
Roche [Member] | |
Licensing Arrangements [Line Items] | |
Proceeds from out-licensed arrangements | 170,000,000 |
Potential milestone receipts | $ 205,000,000 |
OTHER (INCOME)/EXPENSE (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Other Nonoperating Income (Expense) [Abstract] | ||
Interest expense | $ 45 | $ 43 |
Investment income | (33) | (24) |
Provision for restructuring | 164 | 4 |
Litigation and other settlements | (484) | 43 |
Equity in net income of affiliates | (18) | (26) |
Divestiture gains | (127) | (270) |
Royalties and licensing income | (199) | (254) |
Transition and other service fees | (7) | (53) |
Pension charges | 33 | 22 |
Intangible asset impairments | 15 | |
Other | (21) | (20) |
Other (income)/expense | (647) | $ (520) |
Patent-infringement litigation settlement amount | $ 481 |
INCOME TAXES (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Earnings Before Income Taxes | $ 1,955 | $ 1,655 |
Provision for Income Taxes | $ 429 | $ 449 |
Effective tax rate | 21.90% | 27.10% |
Federal statutory tax rate | 35.00% | |
Increase in Effective Income Tax Rate due to Discrete Items | 1.70% | 4.40% |
Reduction of effective tax rate due to adoption of ASU | 2.10% | |
Minimum [Member] | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Decrease in Unrecognized Tax Benefits is Reasonably Possible | $ 255 | |
Maximum [Member] | ||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
Decrease in Unrecognized Tax Benefits is Reasonably Possible | $ 315 |
EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Earnings Per Share [Abstract] | ||
Net earnings attributable to BMS used for Basic and Diluted EPS Calculation | $ 1,574 | $ 1,195 |
Weighted-average common shares outstanding - basic | 1,662 | 1,669 |
Incremental shares attributable to share-based compensation plans | 9 | 11 |
Weighted-average common shares outstanding - diluted | 1,671 | 1,680 |
Earnings per share - basic | $ 0.95 | $ 0.72 |
Earnings per share - diluted | $ 0.94 | $ 0.71 |
RECEIVABLES (Details) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017
USD ($)
|
Mar. 31, 2016
USD ($)
|
Dec. 31, 2016
USD ($)
|
|
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Trade receivables | $ 4,247 | $ 3,948 | |
Charge-Backs and Cash Discounts | (123) | (126) | |
Less allowances | (41) | (48) | |
Net trade receivables | 4,083 | 3,774 | |
Alliance receivables | 897 | 903 | |
Prepaid and refundable income taxes | 243 | 627 | |
Other | 271 | 239 | |
Receivables | 5,494 | $ 5,543 | |
Non-U.S. receivables sold on a nonrecourse basis | $ 120 | $ 159 | |
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers | 65.00% | 66.00% | |
Number Of Largest Pharmaceutical Wholesalers | 3 |
INVENTORIES (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Inventory, Net [Abstract] | ||
Finished goods | $ 415 | $ 310 |
Work in process | 1,038 | 988 |
Raw and packaging materials | 230 | 264 |
Total inventories | 1,683 | 1,562 |
Inventories | 1,384 | 1,241 |
Inventories - other assets | 299 | 321 |
Inventory pending regulatory approval | $ 58 | $ 54 |
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | $ 9,321 | $ 9,173 | |
Less accumulated depreciation | (4,301) | (4,193) | |
Property, plant and equipment | 5,020 | 4,980 | |
Depreciation expense | 166 | $ 103 | |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 107 | 107 | |
Buildings [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 4,952 | 4,930 | |
Machinery, equipment and fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 3,324 | 3,287 | |
Construction in Progress [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | $ 938 | $ 849 |
OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Gross other intangible assets | $ 4,297 | $ 4,469 | |
Less: accumulated amortization | (3,021) | (3,084) | |
Other intangible assets | 1,276 | 1,385 | |
In-process research and development | 32 | 107 | |
Amortization expense | 47 | $ 44 | |
Licensing Agreements [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | 564 | 564 | |
Developed Technology Rights [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | 2,357 | 2,357 | |
Capitalized Software, Intangible Asset [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | $ 1,344 | $ 1,441 |
ACCRUED LIABILITIES (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Payables and Accruals [Abstract] | ||
Rebates and returns | $ 1,677 | $ 1,680 |
Dividends | 646 | 660 |
Research and development | 620 | 718 |
Employee compensation and benefits | 361 | 818 |
Branded Prescription Drug Fee | 257 | 234 |
Restructuring | 182 | 90 |
Royalties | 181 | 246 |
Pension and postretirement benefits | 41 | 44 |
Litigation and other settlements | 36 | 43 |
Other | 776 | 738 |
Accrued liabilities | $ 4,777 | $ 5,271 |
PENSION AND POSTRETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Pension, Postretirement And Postemployment Liabilities Statement [Line Items] | |||
Non-current pension liabilities | $ 490 | $ 600 | |
Defined contribution plan expense | 44 | $ 42 | |
Pension Benefits [Member] | |||
Pension, Postretirement And Postemployment Liabilities Statement [Line Items] | |||
Service cost - benefits earned during the period | 6 | 6 | |
Interest cost on projected benefit obligation | 48 | 51 | |
Expected return on plan assets | (103) | (104) | |
Amortization of prior service credits | (1) | (1) | |
Amortization of net actuarial (gain)/loss | 21 | 19 | |
Curtailments and settlements | 33 | 22 | |
Special termination benefits | 1 | ||
Net periodic benefit cost/(credit) | $ 4 | $ (6) |
4OK ]?Z#_5NHW=5R9@8>%/_35;;-\1U&%=1LX/99C8\PUY-B
M-!?_ R[ '=PK<3E*Q4WXHG(P5HF9Q4D1[&U:.QG6<3K9?YG#X@%T#J!+P%W(
M0Z9$0?E79EF1:34B/?6^9_Z*DP-UO2F],[0BG#GQQGDO!4UH1BZ>:,8<)PQ=
M89(%01S[DH+&4ASI?^'T-AZ_C4K 7:"&AU(]M 074,G^/#:>_P'O"C@4$O]H'KY"+E
MFPL^7X]AY H"#J5Q"LPN=W@!SIV0+>/7I!G.EHZXW#_4/_K>;2\7IN%%\I_-
MU=3'Q]
M7)O6K\.D_Z#A!#H1Z(I 1B-?^0=F6)$K.01J//N.N2N.#]2>3>F2_BC\-UN\
MMME[06F:D[L3FC"G$4,7F'A&$*L^6U#,XD3_H],,YR=HB8GG)TO[S1X72%&!
MU ND__2X6?6(8;:XR08UV2 "V FMQK&6WPYR,CN<0#]!MG(WQ);E?]:<)
M[V[ZPXWO>;,KZM9[%E)MR_7F>2N$Y"K'\$Z]KSW/-^-#R;>RNTW4?=,?*O0/
M4AR& Y-@/+59_ -02P,$% @ P%N;2B9G)')G P E@X !D !X;"]W
M;W)K J-I.[CO5!R*6GI/7.E6PE[X>\X5TQK#.[UB1]TT
M]H.2[97Y3/6W:#NG=J!XTW6%0=^:+O\!4$L#!!0 ( ,!;FTK]\,N/N (
M !L* 9 >&PO=V]R:W-H965TV4\>9F[C.CNWI*5=O_/*%-0%%KM-$_XV=6:[A1HGVL>6Y
MM+_.]B05+QH6+:6@'_4W*^WWTO!?S6 #W!C@UD#[?F00- ;!S2!\:! V!N'-
M(+;9JD.QN5E31>=3P2^.J+>WHN84H4FHL[\UBS;9]C^='JE7SW,
*"%BP/]>\TA\&+8H0 P8I^Q 30]R<%212'X
M=D A< ;#!0KX?D#1?[B%"QL!E3UW.Z_;$-ENO"-+81@,'#P3:$#DBZQ1 F1X&&6UI%8( )"K#
MM^SN!(:.N&$3(C L!( %:1!!0<"820LD\BVX$);S%<5%X-M:%4]Q$=S0)'B*
M"W"HH4T2DB,<&2- 0\:(-SE#=Q\UOF7U+J\:YTFU^CC>'YJW2K52Q_/O=;R]
MS#;GAT)NV^XVUO?U\#%A>&C58?Q0XIV_UBS^ 5!+ P04 " # 6YM*0?OA
M=[@# "*$0 &0 'AL+W=O
!TSSX(O(]! !+T*ES#IO3-)$'Q
M>=O5LP#-()0\1_O5 J\:'3]X%W!SO^\W-(OZ&NZ>Z:67X #O^X#&;MYO_B33
M=Q_PA_JN_U(' %@B]$>,,_OU&B\6CGOT^!@'7T*:_1XX"=$W?"9@&G<
$
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MEOID^33^%6O64<4'S.TU4;IXC4UT/#=;714/<<**Y=0EEAAJ#6R&%\FNA?
M53P.)M9G-=,12[4.CLOJ16JQ>H=T$*B7#/.E,+D8X/WH;_D -"=9R94;2R70
MDN80NEGO-1H_HJQ*V?@!ET]DN;%=;W4SWX%JC-]80H94_E:3<@$.
MC:(2$B;^'6 BFRR^X@B=P2 ?T#Z>3'\9O;\J*+.E*V+86AH><>BJ4'M;=:,Z
MC-[,^A*2>A_[5*K)3H)J::O3YX)D':Q1B2WBR-%^\>C//SLA$9::U9HM2CAI
M4L8'O?+H+X0IX.5+"8\.)5-TT$Z V][E9N]XC4$;9N[W4Z70[ -87@2+B]PZ
MI93C +5;L68Y02?(WWIPZ:R*MT" ;K6'J3HF9T /.V1MZ'K=3MO*0^Z4%#=(
M9G-03-%Y1IFP4E&6=>5L.8YF=_C'T:UZ:LE<'A=SCVF\%45 !V%&UK[